Description: 💙 Thank you to JoggAI for sponsoring this video! Join the JoggAI AvatarX Challenge for a chance to win $10,000 ...

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround.

When electric aircraft developer Joby Aviation in August unveiled its concept for a hybrid-powered, optionally piloted ...

Direct-to-consumer sales of medications often mean lower prices and more convenience for patients.

This comes during a time when when Eli Lilly and Novo Nordisk have been garnering momentum—last week, the FDA added ...

China is likely to press ahead with expanding the global use of the yuan in a gradual and prudent manner during the 15th Five-Year Plan period (2026-30), while continuing to foster a sound environment ...

What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Monday outlined that Weiss executed a sale ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Executive VP Eric Hughes described the pipeline's late-stage assets, including olanzapine LAI on track for FDA submission, DARI, duvakitug, and emrusolmin, citing potential peak sales of over $11 ...

Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues ...

Ultragenyx Pharmaceutical Inc (RARE) reports a 15% revenue increase in Q3 2025, while navigating a net loss and high operating expenses.

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of ...